← Назад до скринера
Hemab Therapeutics Holdings, Inc. Common Stock (COAG)
Ціна$27.81
Усі метрики
Ціна відносно S&P 500 (з поч. року)-29.06%
Середній обсяг торгів за 10 днів0.91M
Середній обсяг торгів за 3 місяці0.91M
Максимум за 52 тижні$36.61
Дохідність з початку року-26.47%
Дохідність за 5 днів0.00%
Дохідність з початку місяця-26.47%
Мінімум за 52 тижні$23.00
Порівняння з галуззю — Біологічні препарати(90)
| Символ | P/S (TTM) | Зростання виручки TTM (р/р) | Валова маржа (TTM) | Зростання EPS (5 років) | Ціна |
|---|---|---|---|---|---|
COAGHemab Therapeutics Holdings, Inc. Common Stock | — | — | — | — | $27.81 |
| AMGNAmgen Inc | 4.80x | 9.07% | 73.95% | 2.93% | $334.72 |
| GILDGilead Sciences Inc | 5.72x | 3.48% | 79.35% | 133.64% | $132.91 |
| ARGXargenx SE American Depositary Shares | 10.79x | 80.59% | 144.51% | — | $800.15 |
| BIIBBiogen Inc. Common Stock | 2.99x | 1.23% | 75.49% | -18.77% | $199.79 |
| BNTXBioNTech SE American Depositary Share | 7.90x | -11.81% | 82.18% | — | $92.61 |
| MRNAModerna, Inc. Common Stock | 9.50x | -29.97% | 35.01% | — | $50.67 |
| NBIXNeurocrine Biosciences Inc | 5.04x | 28.59% | 98.17% | 2.31% | $160.19 |
| EXELExelixis Inc | 5.23x | 7.91% | 96.44% | 31.10% | $50.33 |
| KRYSKrystal Biotech, Inc. Common Stock | 21.92x | 25.15% | 94.17% | — | $313.68 |
| IBRXImmunityBio, Inc. Common Stock | 75.30x | 668.31% | 99.34% | — | $8.17 |
Про акцію
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.